Influence of maintenance therapy on incidence of 2nd line therapy and OS in NSCLC IV

Introduction: One of the strongest rationale for maintenance therapy in NSCLC is the fact that exposure to 2nd line therapy is only 40 – 60% in clinical trials in specialized treatment centers. Even with follow-up intervals of 6 weeks, the 2nd line treatment rate does not seem to increase. We analyzed the exposure of 2nd line therapy as well as OS and PFS in patients with stage IV NSCLC in the subgroups no 2nd line, 2nd line after maintenance and 2nd line without maintenance therapy. Methods: All primary lung cancer cases stage IV in the lung cancer center were analyzed based on the documentation files between 2…